Safety
death, infectious complications, neutropenia, hypokalaemia, leukopenia, hypomagnesemia, anemia, lymphopenia, non-DLT, hypotension, acute kidney injury
NEUTROPENIA, LEUKOPENIA, ADVERSE EVENTS, HYPOMAGNESEMIA, ANEMIA, LYMPHOPENIA, EVENTS
Among the 15 patients evaluable for DLT, three (20%) experienced DLT: two patients had grade 3 hypotension and one developed a grade 3 acute kidney injury, both DLT being considered to be related to cisplatin administration. No death occurred during the DLT evaluation period. Among the 16 patients, five (31.2%) had acute, grade 4 non-DLT adverse events (AE)—all lymphopenias; patients that developed acute, grade 3 non-DLT AE experienced lymphopenia (eight patients, 50%), neutropenia (seven patients, 43.8%), anemia (two patients, 12.5%), hypokalaemia and hypomagnesemia (one patient, 6.25%). All leukopenia events resolved spontaneously without infectious complications (Supplementary Fig. 